Use of recombinant activated factor VII for massive postpartum hemorrhage

Hossain, Nazli; Shamsi, Tahir; Haider, S.M.; Soomro, Nargis; Khan, Naghma; Memon, Ghuffrana Umer; Farzana, Tasneem; Ansari, Saqib Hussain; Triche, Elizabeth W.; Kuczynski, Edward; Lockwood, Charles J.; Paidas, Michael J.

doi:10.1080/00016340701619324

Cited by 34 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the remaining 40 studies with usable information, we included only those reporting more than 10 cases in the final analysis. Thus, we considered 9 studies for this review, [14][15][16][17][18][19][20][21][22] with data on 272 PPH patients (the 31 excluded studies evaluated 57 patients). Figure 1 shows the flow chart of studies included in this chapter.…”

Section: Search Methodsmentioning

confidence: 99%

The Use of Recombinant Activated FVII in Postpartum Hemorrhage

Franchini¹,

Franchi

Bergamini

et al. 2010

Clinical Obstetrics &Amp; Gynecology

128

View full text Add to dashboard Cite

Severe bleeding remains a leading cause of morbidity and mortality in obstetrics. The first-line standard treatment of massive postpartum hemorrhage (PPH) includes medical measures directed at improving uterine tone, replacement of lost intravascular volume, blood and coagulation factors, and surgical or invasive procedures. Recently, a number of case reports or case series have reported the successful "off-label" use of recombinant activated factor VII (rFVIIa) in PPH unresponsive to conventional treatments. In this review, a critical analysis of the published literature on the use of rFVIIa in severe PPH was performed. Overall, a total of 272 PPH women were collected among the largest case series and/or international registries. No randomized controlled trials have been conducted in this area. Currently, the literature data suggest that, at a median dose of 81.5 microg/kg, rFVIIa is effective in stopping or reducing bleeding in 85% of the cases. Finally, on the basis of the evidence from the literature and on own experience, we included some recommendations and an algorithm on the therapeutic role of rFVIIa in the management of PPH.

show abstract

Section: Search Methodsmentioning

confidence: 99%

The Use of Recombinant Activated FVII in Postpartum Hemorrhage

Franchini¹,

Franchi

Bergamini

et al. 2010

Clinical Obstetrics &Amp; Gynecology

128

View full text Add to dashboard Cite

show abstract

“…The risk of maternal death appeared to be lower in women treated with rFVIIa (OR 0.38, 95%CI 0.09-1.60), and remained lower following adjustment for baseline haemoglobin and activated partial thromboplastin time (aPTT) (OR 0.04, 95%CI 0.002-0.83) (43). The risk of subsequent need for hysterectomy is difficult to ascertain, as the drug was administered as a 'last resort' treatment.…”

Section: (D) Should Recombinant Factor Viia Be Offered In the Treatmementioning

confidence: 97%

“…4 Hossain study (43) did not indicate timing of rFVIIa administration in relation to need for procedure.…”

mentioning

confidence: 99%

Nyttig bidrag for å redusere mødredødelighet

Augensen¹

2010

Tidsskriftet

View full text Add to dashboard Cite

“…7 Recombinant activated factor VII (rFVIIa; Novo-SevenÒ, Novo Nordisk, Begsvaerd, Denmark) has been frequently used 'off-label' to treat haemorrhage in patients without primary defects of the coagulation system, such as women with PPH. [8][9][10][11][12] Guidelines for rFVIIa use in PPH have appeared in several countries, 4,7,12,13 and clinical registry data supporting its use have been published from Northern Europe 3 and Italy. 5 The UniSeven registry was established in 2004 to collect data on rFVIIa administration in non-haemophiliac patients from the Czech Republic, Slovakia, Slovenia and Hungary.…”

mentioning

confidence: 98%